NCT01323296

Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: University of Edinburgh · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The investigators wish to examine whether a novel 'nanoparticle' of iron oxide, administered intravenously allows an area of heart muscle damage after heart attack to be visualised using a magnetic resonance scanner.

Detailed description

Using ferumoxtran (Feraheme) as a USPIO contrast agent for magnetic resonance imaging at 3 Tesla, we aim to conduct the first clinical study to examine the utility of this novel contrast agent to image myocardial inflammation after myocardial infarction. We will test the following hypotheses in patients who have suffered recent acute myocardial infarction. 1. Intravenous injection of ferumoxytol accumulates at the site of myocardial infarction and this can be visualised by magnetic resonance imaging. 2. The spatial extent of the MRI signal change evoked by ferumoxytol in the myocardium is proportional to the volume of infarcted myocardium (as assessed by a gadolinium late-enhancement study). 3. Myocardial MRI signal change evoked by ferumoxytol is positively correlated with blood markers of systemic inflammation.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
OTHER	Ferumoxytol	One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)

Timeline

• Start date: 2010-11-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2011-03-25
• Last updated: 2014-12-04

Locations

2 sites across 1 country: United Kingdom